Zhengye Biotechnology (NASDAQ:ZYBT) Given Sell (D-) Rating at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Zhengye Biotechnology (NASDAQ:ZYBT) in a research note released on Tuesday morning,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Zhengye Biotechnology to a “hold” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Zhengye Biotechnology has a consensus rating of “Sell”.

Zhengye Biotechnology Trading Up 1.0%

NASDAQ:ZYBT opened at $2.89 on Tuesday. The company’s 50 day moving average price is $6.73 and its 200-day moving average price is $7.08. Zhengye Biotechnology has a 52 week low of $1.40 and a 52 week high of $14.30.

Institutional Investors Weigh In On Zhengye Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC purchased a new stake in Zhengye Biotechnology in the second quarter worth approximately $174,000. Invesco Ltd. purchased a new stake in Zhengye Biotechnology in the second quarter worth approximately $220,000. Finally, Jane Street Group LLC purchased a new stake in Zhengye Biotechnology in the second quarter worth approximately $1,158,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.